Healius Limited reported a 76.6% rise in underlying EBIT to A$30.2 million for the fiscal year ended June 2026, driven by a 2.1% increase in underlying revenue to A$1.37 billion. Underlying EBITDA climbed 8.1% to A$258.6 million, while pathology revenue grew 1.8% to A$1.33 billion, according to the company's earnings update.
The group also recorded a more than doubling of EBIT at Agilex Biolabs to A$6.4 million, supported by a 14.1% revenue increase to A$43.6 million. Genomic Diagnostics revenue rose 16.9% and clinical trials revenue surged 92.9%. Corporate cost savings totaled A$24.4 million, exceeding targets, while net debt stood at A$32.8 million compared with a net cash position of A$57.2 million a year earlier.
Shares of Healius fell 3.37% to A$0.43 in recent trading, extending declines from a 52-week high of A$1.07. The company implemented restructuring measures, including the closure of 100 collection sites and a 24.3% reduction in full-time equivalent roles in its main lab. Pathology labor costs were held flat despite the staffing reductions.
Digital transformation efforts progressed, with over 80% of accredited collection center episodes processed through Medway and 220,000 patient appointments booked via new capabilities since August 2025. E-referral volumes increased 28% year-over-year, though GP attendances declined 0.9% over the 12-month period.
Outlook for fiscal 2027 included EBIT guidance of A$39.7 million, in line with consensus, though this incorporated a A$15 million cost impact from the Fair Work Commission's gender undervaluation ruling and a 4.75% modern award increase. Excluding this charge, EBIT would approximate A$54.7 million. Healius now expects to achieve its target of mid-to-high single-digit EBIT margins by December 2028, later than previously anticipated due to cost pressures and reduced GP attendances.
Capital expenditure totaled A$42 million in fiscal 2026, with spending expected to decline in fiscal 2027 as the company targets cash flow positivity. The group maintained a current ratio of 1.99 and a debt-to-equity ratio of 0.13.
